Biologic and Clinical Features of Benign Solid and Cystic Lesions of the Liver

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 7, 2011, Pages 547-562.e4

  Shaked, Oren ^a   Siegelman, Evan S ^a   Olthoff, Kim ^b   Reddy, K Rajender ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenoma; Cystadenoma; Hemangioma; Hepatocellular; Hyperplasia; Polycystic Liver Disease

Indexed keywords

ALPHA FETOPROTEIN; ANDROGEN; ANDROGEN RECEPTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA CATENIN; CA 19-9 ANTIGEN; ESTROGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; POLYCYSTIN 1; POLYCYSTIN 2;

ADENOMATOSIS; AGE; ANGIOMYOLIPOMA; ARTIFICIAL EMBOLISM; CANCER SURGERY; CARCINOGENESIS; CAROLI DISEASE; CELL PROLIFERATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASONOGRAPHY; CYSTADENOMA; DIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; ESTROGEN THERAPY; FENESTRATION; FOLLOW UP; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 3; HAMARTOMA; HEMANGIOENDOTHELIOMA; HEPATOBILIARY CYSTADENOMA; HUMAN; INCIDENCE; INFECTION; LIVER ADENOMA; LIVER ADENOMATOSIS; LIVER BIOPSY; LIVER CYST; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LIVER HEMORRHAGE; LIVER HEMOSIDEROSIS; LIVER HYPERPLASIA; LIVER POLYCYSTIC DISEASE; LIVER RESECTION; LIVER RUPTURE; LIVER TRANSPLANTATION; LIVER TUMOR; MESENCHYMAL HAMARTOMA; NODULAR REGENERATIVE HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PLASMA CELL GRANULOMA; PORTAL HYPERTENSION; PREGNANCY; PREVALENCE; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; SEX RATIO; SIMPLE HEPATIC CYST; TELANGIECTATIC HEPATOCELLULAR ADENOMA; TREATMENT INDICATION; TUMOR VOLUME;

EID: 79959351115     PISSN: 15423565     EISSN: 15423565     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.03.007     Document Type: Review

References (155)

1. Edmondson H.A. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology, Ser. 1, Fasc. 25 1958, Armed Forces Institute of Pathology, Washington DC.
2. Buscarini L., Fornari F., Civardi G., et al. Laparoscopy integrates ultrasound and ultrasound guided biopsy for diagnosis of benign liver tumors. Acta Endosc 1993, 23:27-36.
3. Rooks J.B., Ory H.W., Ishak K.G., et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979, 242:644-648.
4. Dokmak S., Paradis V., Vilgrain V., et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009, 137:1698-1705.
5. Flejou J.F., Barge J., Menu Y., et al. Liver adenomatosis. An entity distinct from liver adenoma?. Gastroenterology 1985, 89:1132-1138.
6. Ribeiro A., Burgart L.J., Nagorney D.M., et al. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998, 4:388-398.
7. Deneve J.L., Pawlik T.M., Cunningham S., et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009, 16:640-648.
8. Edmondson H.A., Reynolds T.B., Henderson B., et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977, 86:180-182.
9. Bühler H., Pirovino M., Akobiantz A., et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982, 82:775-782.
10. Heinemann L.A., Weimann A., Gerken G., et al. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care 1998, 3:194-200.
11. Cohen C., Lawson D., DeRose P.B. Sex and androgenic steroid receptor expression in hepatic adenomas. Hum Pathol 1998, 29:1428-1432.
12. Kent D.R., Nissen E.D., Nissen S.E., et al. Effect of pregnancy on liver tumor associated with oral contraceptives. Obstet Gynecol 1978, 51:148-151.
13. Hernandez-Nieto L., Bruguera M., Bombi J., et al. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Cancer 1977, 40:1761-1764.
14. Martin N.M., Abu Dayyeh B.K., Chung R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008, 14:4573-4575.
15. Triantafyllopoulou M., Whitington P.F., Melin-Aldana H., et al. Hepatic adenoma in an adolescent with elevated androgen levels. J Pediatr Gastroenterol Nutr 2007, 44:640-642.
16. Labrune P., Trioche P., Duvaltier I., et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997, 24:276-279.
17. Parker P., Burr I., Slonim A., et al. Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology 1981, 81:534-536.
18. Cassiman D., Libbrecht L., Verslype C., et al. An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen Storage Disease type Ia. J Hepatol 2010, 53:213-217.
19. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993, 152(Suppl 1):S63-S70.
20. Reddy S.K., Kishnani P.S., Sullivan J.A., et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol 2007, 47:658-663.
21. Lee P.U., Roberts L.R., Kaiya J.K., et al. Hepatic adenomas associated with anti-epileptic drugs: a case series and imaging review. Abdom Imaging 2010, 35:208-211.
22. Ishak K.G., Goodman Z.D., Stocker J.T. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology, Ser. 3, Fasc. 25 2001, Armed Forces Institute of Pathology, Washington DC.
23. Vana J., Murphy G.P., Aronoff B.L., et al. Primary liver tumors and oral contraceptives. Results of a survey. JAMA 1977, 238:2154-2158.
24. Bioulac-Sage P., Blanc J.F., Rebouissou S., et al. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007, 13:2649-2654.
25. Bioulac-Sage P., Laumonier H., Couchy G., et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009, 50:481-489.
26. Zucman-Rossi J., Jeannot E., Nhieu J.T., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
27. Laumonier H., Bioulac-Sage P., Laurent C., et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008, 48:808-818.
28. Grazioli L., Morana G., Kirchin M.A., et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005, 236:166-177.
29. Brancatelli G., Federle M.P., Vullierme M.P., et al. CT and MR imaging evaluation of hepatic adenoma. J Comput Assist Tomogr 2006, 30:745-750.
30. Ricci P., Cantisani V., D'Onofrio M., et al. Behavior of hepatocellular adenoma on real-time low-mechanical index contrast-enhanced ultrasonography with a second-generation contrast agent. J Ultrasound Med 2008, 27:1719-1726.
31. Ahmad I., Iyer A., Marginean C.E., et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol 2009, 40:726-734.
32. Bioulac-Sage P., Rebouissou S., Thomas C., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
33. Cai Y.R., Gong L., Teng X.Y., et al. Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol 2009, 15:4695-4708.
34. Gong L., Li Y.H., Su Q., et al. Use of X-chromosome inactivation pattern and laser microdissection to determine the clonal origin of focal nodular hyperplasia of the liver. Pathology 2009, 41:348-355.
35. Iyer A., Robert M.E., Bifulco C.B., et al. Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol 2008, 39:1370-1377.
36. Cho S.W., Marsh J.W., Steel J., et al. Surgical management of hepatocellular adenoma: take it or leave it?. Ann Surg Oncol 2008, 15:2795-2803.
37. Ribeiro Junior M.A., Chaib E., Saad W.A., et al. Surgical management of spontaneous ruptured hepatocellular adenoma. Clinics (Sao Paulo) 2009, 64:775-779.
38. Maoz D., Sharon E., Chen Y., et al. Spontaneous hepatic rupture: 13-year experience of a single center. Eur J Gastroenterol Hepatol 2010, 22:997-1000.
39. Papanikolaou V., Giakoustidis D., Patsiaura K., et al. Management of a giant ruptured hepatocellular adenoma. Report of a case. Hippokratia 2007, 11:86-88.
40. Foster J.H., Berman M.M. The malignant transformation of liver cell adenomas. Arch Surg 1994, 129:712-717.
41. Steinbrecher U.P., Lisbona R., Huang S.N., et al. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981, 26:1045-1050.
42. Mariani A.F., Livingstone A.S., Pereiras R.V., et al. Progressive enlargement of an hepatic cell adenoma. Gastroenterology 1979, 77:1319-1325.
43. Gordon S.C., Reddy K.R., Livingstone A.S., et al. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986, 105:547-549.
44. Tesluk H., Lawrie J. Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981, 105:296-299.
45. van der Windt D.J., Kok N.F., Hussain S.M., et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006, 93:1495-1502.
46. Farges O., Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010, 27:32-38.
47. Rhim H., Lim H.K., Kim Y.S., et al. Percutaneous radiofrequency ablation of hepatocellular adenoma: initial experience in 10 patients. J Gastroenterol Hepatol 2008, 23:e422-e427.
48. Erdogan D., van Delden O.M., Busch O.R., et al. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Interv Radiol 2007, 30:1252-1258.
49. Leese T., Farges O., Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988, 208:558-564.
50. Veteläinen R., Erdogan D., de Graaf W., et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 2008, 28:499-508.
51. Chiche L., Dao T., Salamé E., et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg 2000, 231:74-81.
52. Lee S.H., Hahn S.T. Treatment of multiple hepatic adenomatosis using transarterial chemoembolization: a case report. Cardiovasc Interv Radiol 2004, 27:563-565.
53. Fujita S., Kushihata F., Herrmann G.E., et al. Combined hepatic resection and radiofrequency ablation for multiple hepatic adenomas. J Gastroenterol Hepatol 2006, 21:1351-1354.
54. Arvind N., Duraimurugan D., Rajkumar J.S. Hepatic adenomatosis--a rare double complication of multiple adenoma rupture and malignant transformation. Indian J Gastroenterol 2006, 25:209-210.
55. Attal P., Vilgrain V., Brancatelli G., et al. Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases. Radiology 2003, 228:465-472.
56. Bioulac-Sage P., Rebouissou S., Sa Cunha A., et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005, 128:1211-1218.
57. Paradis V., Champault A., Ronot M., et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007, 46:140-146.
58. Takayassu T.C., Marchiori E., Eiras A., et al. Telangiectatic adenoma - computed tomography and magnetic resonance findings: a case report and review of the literature. Cases J 2009, 2:24.
59. Paradis V., Benzekri A., Dargere D., et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004, 126:1323-1329.
60. Wanless I.R., Sapp H., Guindi M., et al. The pathogenesis of focal nodular hyperplasia: an hypothesis based on histologic review of 20 lesions including 3 occurring in early biliary cirrhosis. Hepatology 2006, 44:491A.
61. Sato Y., Harada K., Ikeda H., et al. Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation. Hum Pathol 2009, 40:181-188.
62. Karhunen P.J. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986, 39:183-188.
63. Nguyen B.N., Fléjou J.F., Terris B., et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999, 23:1441-1454.
64. Wanless I.R., Mawdsley C., Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985, 5:1194-1200.
65. Mathieu D., Kobeiter H., Cherqui D., et al. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. Lancet 1998, 352:1679-1680.
66. Weimann A., Mössinger M., Fronhoff K., et al. Pregnancy in women with observed focal nodular hyperplasia of the liver. Lancet 1998, 351:1251-1252.
67. Scalori A., Tavani A., Gallus S., et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002, 186:195-197.
68. Cherqui D., Rahmouni A., Charlotte F., et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995, 22:1674-1681.
69. Luciani A., Kobeiter H., Maison P., et al. Focal nodular hyperplasia of the liver in men: is presentation the same in men and women?. Gut 2002, 50:877-880.
70. Mathieu D., Zafrani E.S., Anglade M.C., et al. Association of focal nodular hyperplasia and hepatic hemangioma. Gastroenterology 1989, 97:154-157.
71. Laurent C., Trillaud H., Lepreux S., et al. Association of adenoma and focal nodular hyperplasia: experience of a single French academic center. Comp Hepatol 2003, 2:6.
72. Wanless I.R., Albrecht S., Bilbao J., et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol 1989, 2:456-462.
73. Huppertz A., Haraida S., Kraus A., et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology 2005, 234:468-478.
74. Liu Y.J., Fan W.J., Yuan Z.D., et al. Research on focal nodular hyperplasia with MSCT and postprocessing. World J Gastroenterol 2009, 15:4838-4843.
75. Lin M.C., Tsay P.K., Ko S.F., et al. Triphasic dynamic CT findings of 63 hepatic focal nodular hyperplasia in 46 patients: correlation with size and pathological findings. Abdom Imaging 2008, 33:301-307.
76. Trillaud H., Bruel J.M., Valette P.J., et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009, 15:3748-3756.
77. Kuo Y.H., Wang J.H., Lu S.N., et al. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound 2009, 37:132-137.
78. Demarco M.P., Shen P., Bradley R.F., et al. Intraperitoneal hemorrhage in a patient with hepatic focal nodular hyperplasia. Am Surg 2006, 72:555-559.
79. Rahili A., Cai J., Trastour C., et al. Spontaneous rupture and hemorrhage of hepatic focal nodular hyperplasia in Lobus caudatus. J Hepato Biliary Pancreat Surg 2005, 12:138-142.
80. Haubert L., Yearsley M., Bloomston M. Hepatocellular carcinoma arising within focal nodular hyperplasia. Am Surg 2010, 76:335-336.
81. Paradis V., Laurent A., Flejou J.F., et al. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997, 26:891-895.
82. Charny C.K., Jarnagin W.R., Schwartz L.H., et al. Management of 155 patients with benign liver tumours. Br J Surg 2001, 88:808-813.
83. Amesur N., Hammond J.S., Zajko A.B., et al. Management of unresectable symptomatic focal nodular hyperplasia with arterial embolization. J Vasc Interv Radiol 2009, 20:543-547.
84. Hedayati P., VanSonnenberg E., Shamos R., et al. Treatment of symptomatic focal nodular hyperplasia with percutaneous radiofrequency ablation. J Vasc Interv Radiol 2010, 21:582-585.
85. Gibney R.G., Hendin A.P., Cooperberg P.L. Sonographically detected hepatic hemangiomas: absence of change over time. AJR Am J Roentgenol 1987, 149:953-957.
86. Rungsinaporn K., Phaisakamas T. Frequency of abnormalities detected by upper abdominal ultrasound. J Med Assoc Thai 2008, 91:1072-1075.
87. Adam Y.G., Huvos A.G., Fortner J.G. Giant hemangiomas of the liver. Ann Surg 1970, 172:239-245.
88. Gandolfi L., Leo P., Solmi L., et al. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 1991, 32:677-680.
89. Saegusa T., Ito K., Oba N., et al. Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med 1995, 34:207-211.
90. Conter R.L., Longmire W.P. Recurrent hepatic hemangiomas. Possible association with estrogen therapy. Ann Surg 1988, 207:115-119.
91. Lui W., Zhang S., Hu T., et al. Sex hormone receptors of hemangiomas in children. Chin Med J (Engl) 1997, 110:349-351.
92. Xiao X., Hong L., Sheng M. Promoting effect of estrogen on the proliferation of hemangioma vascular endothelial cells in vitro. J Pediatr Surg 1999, 34:1603-1605.
93. Gemer O., Moscovici O., Ben-Horin C.L., et al. Oral contraceptives and liver hemangioma: a case-control study. Acta Obstet Gynecol Scand 2004, 83:1199-1201.
94. Tait N., Richardson A.J., Muguti G., et al. Hepatic cavernous haemangioma: a 10 year review. Aust N Z J Surg 1992, 62:521-524.
95. Park W.C., Rhillips R. The role of radiation therapy in the management of hemangiomas of the liver. JAMA 1970, 212:1496-1498.
96. Herman P., Costa M.L., Machado M.A., et al. Management of hepatic hemangiomas: a 14-year experience. J Gastrointest Surg 2005, 9:853-859.
97. Kasabach H., Merritt K. Capillary hemangioma with extensive purpura. Report of a case. Am J Dis Child 1940, 59:1063-1070.
98. Quaia E., Calliada F., Bertolotto M., et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004, 232:420-430.
99. Wen Y.L., Kudo M., Zheng R.Q., et al. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol 2004, 182:1019-1026.
100. Nghiem H.V., Bogost G.A., Ryan J.A., et al. Cavernous hemangiomas of the liver: enlargement over time. AJR Am J Roentgenol 1997, 169:137-140.
101. Farges O., Daradkeh S., Bismuth H. Cavernous hemangiomas of the liver: are there any indications for resection?. World J Surg 1995, 19:19-24.
102. Sewell J.H., Weiss K. Spontaneous rupture of hemangioma of the liver. A review of the literature and presentation of illustrative case. Arch Surg 1961, 83:729-733.
103. Fu X.H., Lai E.C., Yao X.P., et al. Enucleation of liver hemangiomas: is there a difference in surgical outcomes for centrally or peripherally located lesions?. Am J Surg 2009, 198:184-187.
104. Hering J., Garrean S., Saied A., et al. Use of radio frequency hepatic parenchymal transection device in hepatic hemangioma resection: early experience and lessons learned. HPB (Oxford) 2007, 9:319-323.
105. Silverman S.G., Tuncali K., Adams D.F., et al. MR imaging-guided percutaneous cryotherapy of liver tumors: initial experience. Radiology 2000, 217:657-664.
106. Ferraz A.A., Sette M.J., Maia M., et al. Liver transplant for the treatment of giant hepatic hemangioma. Liver Transpl 2004, 10:1436-1437.
107. Ikegami T., Soejima Y., Taketomi A., et al. Extracorporeal hepatic resection for unresectable giant hepatic hemangiomas. Liver Transpl 2008, 14:115-117.
108. Nakanuma Y. Nodular regenerative hyperplasia of the liver: retrospective survey in autopsy series. J Clin Gastroenterol 1990, 12:460-465.
109. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990, 11:787-797.
110. Biecker E., Trebicka J., Fischer H.P., et al. Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease. Z Gastroenterol 2006, 44:395-398.
111. Ferlitsch A., Teml A., Reinisch W., et al. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007, 102:2495-2503.
112. Trotter J.F., Everson G.T. Benign focal lesions of the liver. Clin Liver Dis 2001, 5:17-42.
113. Stromeyer F.W., Ishak K.G. Nodular transformation (nodular "regenerative" hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol 1981, 12:60-71.
114. Laharie D., Vergniol J., Bioulac-Sage P., et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010, 22:487-493.
115. Boyer T.D. Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension. Curr Gastroenterol Rep 2008, 10:30-35.
116. Tateo M., Sebagh M., Bralet M.P., et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008, 14:1194-1198.
117. Sanfelippo P.M., Beahrs O.H., Weiland L.H. Cystic disease of the liver. Ann Surg 1974, 179:922-925.
118. Lee Y.S. The pattern of liver diseases in Singapore. An autopsy study. Trop Geogr Med 1979, 31:69-74.
119. Gaines P.A., Sampson M.A. The prevalence and characterization of simple hepatic cysts by ultrasound examination. Br J Radiol 1989, 62:335-337.
120. Larssen T.B., Rørvik J., Hoff S.R., et al. The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study. Clin Radiol 2005, 60:1026-1029.
121. Regev A., Reddy K.R., Berho M., et al. Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. J Am Coll Surg 2001, 193:36-45.
122. Taylor B.R., Langer B. Current surgical management of hepatic cyst disease. Adv Surg 1997, 31:127-148.
123. Zhang Y.L., Yuan L., Shen F., et al. Hemorrhagic hepatic cysts mimicking biliary cystadenoma. World J Gastroenterol 2009, 15:4601-4603.
124. Spiegel R.M., King D.L., Green W.M. Ultrasonography of primary cysts of the liver. AJR Am J Roentgenol 1978, 131:235-238.
125. Akiyama T., Inamori M., Saito S., et al. Levovist ultrasonography imaging in intracystic hemorrhage of simple liver cyst. World J Gastroenterol 2008, 14:805-807.
126. Horsmans Y., Laka A., Gigot J.F., et al. Serum and cystic fluid CA 19-9 determinations as a diagnostic help in liver cysts of uncertain nature. Liver 1996, 16:255-257.
127. Inan N., Arslan A., Akansel G., et al. Diffusion-weighted imaging in the differential diagnosis of simple and hydatid cysts of the liver. AJR Am J Roentgenol 2007, 189:1031-1036.
128. Miliadis L., Giannakopoulos T., Boutsikos G., et al. Spontaneous rupture of a large non-parasitic liver cyst: a case report. J Med Case Rep 2010, 4:2.
129. Fabrizzi G., Lanza C., Bolli V., et al. Symptomatic hepatic cyst in a child: treatment with single-shot injection of tetracycline hydrochloride. Pediatr Radiol 2009, 39:1091-1094.
130. Koea J.B. Cystic lesions of the liver: 6 years of surgical management in New Zealand. N Z Med J 2008, 121:61-69.
131. Mazza O.M., Fernandez D.L., Pekolj J., et al. Management of nonparasitic hepatic cysts. J Am Coll Surg 2009, 209:733-739.
132. Gall T.M., Oniscu G.C., Madhavan K., et al. Surgical management and longterm follow-up of non-parasitic hepatic cysts. HPB (Oxford) 2009, 11:235-241.
133. Loehe F., Globke B., Marnoto R., et al. Long-term results after surgical treatment of nonparasitic hepatic cysts. Am J Surg 2010, 200:23-31.
134. Gigot J.F., Jadoul P., Que F., et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?. Ann Surg 1997, 225:286-294.
135. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009, 76:149-168.
136. Drenth J.P., te Morsche R.H., Smink R., et al. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 2003, 33:345-347.
137. Davila S., Furu L., Gharavi A.G., et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 2004, 36:575-577.
138. Kwok M.K., Lewin K.J. Massive hepatomegaly in adult polycystic liver disease. Am J Surg Pathol 1988, 12:321-324.
139. Alvaro D., Mancino M.G., Onori P., et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006, 12:3537-3545.
140. Chauveau D., Fakhouri F., Grünfeld J.P. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 2000, 11:1767-1775.
141. van Keimpema L., de Koning D.B., van Hoek B., et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011, 31:92-98.
142. Waanders E., van Keimpema L., Brouwer J.T., et al. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int 2009, 29:1389-1395.
143. Schnelldorfer T., Torres V.E., Zakaria S., et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009, 250:112-118.
144. Nakaoka R., Das K., Kudo M., et al. Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience. AJR Am J Roentgenol 2009, 193:1540-1545.
145. van Keimpema L., Nevens F., Vanslembrouck R., et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137:1661-1668. e1-2.
146. Devaney K., Goodman Z.D., Ishak K.G. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 1994, 18:1078-1091.
147. Ishak K.G., Willis G.W., Cummins S.D., et al. Biliary cystadenoma and cystadenocarcinoma: report of 14 cases and review of the literature. Cancer 1977, 39:322-338.
148. Marsh J.L., Dahms B., Longmire W.P. Cystadenoma and cystadenocarcinoma of the biliary system. Arch Surg 1974, 109:41-43.
149. Abdul-Al H.M., Makhlouf H.R., Goodman Z.D. Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. Virchows Arch 2007, 450:691-697.
150. Hernandez Bartolome M.A., Fuerte Ruiz S., Manzanedo Romero I., et al. Biliary cystadenoma. World J Gastroenterol 2009, 15:3573-3575.
151. Choi H.K., Lee J.K., Lee K.H., et al. Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol 2010, 44:289-293.
152. Erdogan D., Busch O.R., Rauws E.A., et al. Obstructive jaundice due to hepatobiliary cystadenoma or cystadenocarcinoma. World J Gastroenterol 2006, 12:5735-5738.
153. Del Poggio P., Buonocore M. Cystic tumors of the liver: a practical approach. World J Gastroenterol 2008, 14:3616-3620.
154. Hansman M.F., Ryan J.A., Holmes J.H., et al. Management and long-term follow-up of hepatic cysts. Am J Surg 2001, 181:404-410.
155. Marrone G., Maggiore G., Carollo V., et al. Biliary cystadenoma with bile duct communication depicted on liver-specific contrast agent-enhanced MRI in a child. Pediatr Radiol 2011, 41:121-124.